<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6344542</article-id><article-id pub-id-type="publisher-id">36714</article-id><article-id pub-id-type="doi">10.1038/s41598-018-36714-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Avocado (<italic>Persea americana</italic>) fruit extract (2<italic>R</italic>,4<italic>R</italic>)-1,2,4-trihydroxyheptadec-16-yne inhibits dengue virus replication via upregulation of NF-&#x003ba;B&#x02013;dependent induction of antiviral interferon responses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yu-Hsuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tseng</surname><given-names>Chin-Kai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Ho-Cheng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Chih-Ku</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Chun-Kuang</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ih-Sheng</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chang</surname><given-names>Hsun-Shuo</given-names></name><address><email>hschang@kmu.edu.tw</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Jin-Ching</given-names></name><address><email>jclee@kmu.edu.tw</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3255</institution-id><institution-id institution-id-type="GRID">grid.64523.36</institution-id><institution>Institute of Basic Medical Sciences, College of Medicine, </institution><institution>National Cheng Kung University, </institution></institution-wrap>Tainan, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Graduate Institute of Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Department of Biotechnology, College of Life Science, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0531 9758</institution-id><institution-id institution-id-type="GRID">grid.412036.2</institution-id><institution>Doctoral Degree Program in Marine Biotechnology, College of Marine Sciences, </institution><institution>National Sun Yat-Sen University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>School of Pharmacy, College of Pharmacy, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Graduate Institute of Natural Products, College of Pharmacy, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution>Research Center for Natural Products and Drug Development, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0620 9374</institution-id><institution-id institution-id-type="GRID">grid.412027.2</institution-id><institution>Department of Medical Research, </institution><institution>Kaohsiung Medical University Hospital, </institution></institution-wrap>Kaohsiung, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>9</volume><elocation-id>423</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Dengue virus (DENV) caused millions of infections around the world annually. Co-infection with different serotypes of DENV is associated with dengue hemorrhagic shock syndrome, leading to an estimate of 50% death rate. No approved therapies are currently available for the treatment of DENV infection. Hence, novel anti-DENV agents are urgently needed for medical therapy. Here we demonstrated that a natural product (2&#x02009;<italic>R</italic>,4&#x02009;<italic>R</italic>)-1,2,4-trihydroxyheptadec-16-yne (THHY), extracted from avocado (<italic>Persea americana</italic>) fruit, can inhibit DENV-2 replication in a concentration-dependent manner and efficiently suppresses replication of all DENV serotypes (1&#x02013;4). We further reveal that the NF-&#x003ba;B-mediated interferon antiviral response contributes to the inhibitory effect of THHY on DENV replication. Using a DENV-infected ICR suckling mouse model, we found that THHY treatment caused an increased survival rate among mice infected with DENV. Collectively, these findings support THHY as a potential agent to control DENV infection.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004694</institution-id><institution>Kaohsiung Medical University (KMU)</institution></institution-wrap></funding-source><award-id>KMU-DK108010</award-id><award-id>KMU-DK107011</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Jin-Ching</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004663</institution-id><institution>Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan)</institution></institution-wrap></funding-source><award-id>MOST104-2320-B-037-025-MY3</award-id><award-id>MOST107-2311-B-037-005-MY3</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Jin-Ching</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100006578</institution-id><institution>Chi Mei Medical Center</institution></institution-wrap></funding-source><award-id>107CM-KMU-03</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Jin-Ching</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Dengue virus (DENV) belongs to the Flavivirus genus in the <italic>Flaviviridae</italic> family<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. DENV contains an ~11-kb a positive single-stranded genomic RNA which encodes a single polypeptide<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. The polyprotein is cleaved by viral and host protease to generate mature structural and nonstructural proteins, including C, prM, E, and NS1~NS5 proteins<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. DENV infects over 390 million people and causes tens of thousands of deaths every year in the tropical and subtropical countries<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The symptoms of DENV-infected patients range from classic flu-like dengue fever (DF) to severe life-threatening diseases including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. DHF is characterized by symptoms of plasma leakage, thrombocytopenia, liver enlargement, and hemoconcentration<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. DSS is the most serious complication of DHF, which occurs when circulatory failure is detected in addition to DHF symptoms<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. DEVN is divided into 4 serotypes (DENV-1&#x02013;4), which are considered regarding the clinical manifestations of dengue fever<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Cross-infection by different serotypes of DENV increases the risk of DHF and DSS progression<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Nowadays, non-FDA-approved medicines are available to cure DENV infection and DENV-related diseases; therefore, development of new therapeutic drugs or supplements against DENV infection is an important issue.</p><p id="Par3">The innate immune responses, especially the type I interferon (IFN-I) pathway, are the important action of early host defense against pathogen<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Virus infection is recognized by pattern-recognition receptors (PRRs), which subsequently activate several transcription factors, such as nuclear factor-kappa B (NF-&#x003ba;B)<sup><xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref></sup>. In normal conditions, NF-&#x003ba;B is retained in the cytoplasm in an inactive form by binding to inhibitors of &#x003ba;B&#x003b1; (I&#x003ba;B&#x003b1;). Upon pathogen stimulation, I&#x003ba;B kinase (IKK) activation initiates I&#x003ba;B&#x003b1; phosphorylation and the degradation of I&#x003ba;B&#x003b1;, which leads to the translocation of NF-&#x003ba;B into the nucleus to trigger IFN regulatory factor (IRF) and IFN-I expression and secretion. IFN-I bound to cell surface IFN receptor (IFNAR) phosphorylates Jak1 and 2, and then subsequently phosphorylated transcription factors STAT1 and STAT2<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Subsequently, phosphorylated STAT1 and STAT2 form the transcription complex ISGF3 with IRF9<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and enter the nucleus to trigger IFN-sensitive response element (ISRE) for the expression of antiviral IFN-stimulated genes (ISGs), including 2&#x02032;&#x02013;5&#x02032;-oligoadenylate synthetase (OAS)1, OAS2, OAS3, and protein kinase R (PKR). Activation of these ISGs leads to the inhibition of virus replication<sup><xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref></sup>. In contrast, antiviral IFN-mediated responses can be hindered by viruses, for example, DENV NS2B/NS3 protease, NS5, and NS4B can block IFN signaling via different mechanisms<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. However, increasing reports demonstrate that enhancement of endogenous IFN and downstream antiviral gene expression by compounds or natural products can overcome DENV suppression of IFN responses to effectively inhibit DENV infection <italic>in vitro</italic> and <italic>in vivo</italic>, although the detailed mechanism is not yet clearly identified<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. Therefore, enhancement of antiviral IFN is still considered a potential antiviral strategy against DENV replication.</p><p id="Par4"><italic>Persea americana</italic> Mill. (<italic>P</italic>. <italic>americana</italic>) belongs to the family Lauraceae, which is known as avocado and widely grows in tropical and subtropical regions<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. The fruit, stem, and leaf of avocado are widely used in ethno-medicine<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Particularly, the avocado fruit contains lots of nutrients such as vitamin E, vitamin B, potassium and monosaturated fatty acids<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, which have been reported to exhibit several bioactive properties such as antibacterial<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, antiviral<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, antioxidant<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, anti-atherosclerotic<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, hepatoprotective, and other activities<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. The bioactive components of avocado contain monoterpenoids, sesquiterpenoids, triterpenoids, flavonoids, alkaloids, steroids, carotenoids and long-chain fatty alcohol derivatives<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. In the present study, we performed a drug screen of several compounds isolated from the unripe fruit of avocado<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, including oleic acid (OA), (2&#x02009;<italic>R</italic>,4&#x02009;<italic>R</italic>)-1,2,4-trihydroxyheptadec-16-ene (THHE), (2&#x02009;<italic>R</italic>,4&#x02009;<italic>R</italic>)-1,2,4-trihydroxyheptadec-16-yne (THHY), avocadenol A, avocadenol C, and avocadoin, and found that THHY exhibited anti-DENV activity without cytotoxicity. We next characterized that THHY inhibits DENV infection through induction of NF-&#x003ba;B-mediated antiviral IFN responses. Finally, we assessed the potential of THHY as a dietary supplement used for prevention of lethal DENV replication using a DENV-infected ICR suckling mouse model.</p></sec><sec id="Sec2" sec-type="results"><title>Results and Discussion</title><sec id="Sec3"><title>Avocado extract THHY exhibits anti-DENV activity</title><p id="Par5">Based on the primary anti-DENV screening of several constituents extracted from avocado using a cell-based DENV infectious system, we identified a component (2&#x02009;<italic>R</italic>,4&#x02009;<italic>R</italic>)-1,2,4-trihydroxyheptadec-16-yne (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref>), named THHY, with significant anti-DENV activity. To further confirm the anti-DENV activity of THHY, DENV-infected Huh-7 was incubated with THHY at doses of 0, 1, 5, 10, and 20&#x02009;&#x003bc;M. The RNA and protein were harvested to analyze DENV RNA and protein levels at day 3 post-infection, respectively. THHY significantly suppressed DENV-2 RNA and protein synthesis, with EC<sub>50</sub> values of 10.98&#x02009;&#x000b1;&#x02009;1.9&#x02009;&#x003bc;M. As expected, the THHY also inhibited the DENV-2 protein synthesis when compared to the non-THHY treated DENV-infected cells, in which the ribavirin was served as a positive control (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>). In the meantime, the results of the MTS assay indicated no significant cytotoxicity at the effective concentration (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1D</xref>). Additionally, we further determined the anti-DENV activity of THHY on DENV-1, -2, -3 and -4 (EC<sub>50</sub> values of 14.61&#x02009;&#x000b1;&#x02009;2.4, 10.98&#x02009;&#x000b1;&#x02009;1.9, 12.87&#x02009;&#x000b1;&#x02009;1.7 and 14.61&#x02009;&#x000b1;&#x02009;2.1&#x02009;&#x003bc;M) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1E</xref>). Moreover, we performed a time-dependent antiviral activity assay in Huh-7 cells. The DENV-infected cells were treated with 20&#x02009;&#x003bc;M of THHY for different period of time. Following 1, 2, and 3 days post-infection, cell lysates were harvested to analyze DENV protein levels by western blotting. The data indicated that THHY inhibited DENV replication in a time-dependent manner (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1F</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>Avocado extract THHY exhibits anti-DENV effect <italic>in vitro</italic>. (<bold>A</bold>) Structure of THHY. (B-C) DENV RNA replication and protein synthesis were inhibited by THHY. DENV-infected Huh-7 cells were incubated with 0, 1, 5, 10 and 20&#x02009;&#x003bc;M of THHY for 3 days. The treatment of 50&#x02009;&#x003bc;M ribavirin was served as a positive control. The treatment of 0.1% DMSO, marked &#x0201c;0&#x0201d;, was served as a negative control. Total cellular RNA and protein were harvested for analysis of DENV (<bold>B</bold>) RNA replication and (<bold>C</bold>) protein synthesis levels by qRT-PCR and western blotting, respectively. (<bold>D</bold>) Cell viability of THHY. Huh-7 cells were incubated with indicated concentrations of THHY, and the cell viability was determined by MTS assay after 3 days. (<bold>E</bold>) THHY inhibits replication of 4 serotypes of DENV. Huh-7 cells were infected by 4 serotypes of DENV followed by THHY treatment at concentration of 0 (white bar), 5 (black bar) and 20 (grey bar) &#x003bc;M. Cellular RNA was collected for analysis of RNA levels of DENV at day 3 post-treatment. (<bold>F</bold>) THHY time-dependently inhibits DENV replication. Error bars represent the means&#x02009;&#x000b1;&#x02009;SD from 3 independent experiments (n&#x02009;=&#x02009;3). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="41598_2018_36714_Fig1_HTML" id="d29e613"/></fig></p></sec><sec id="Sec4"><title>THHY inhibits DENV replication by NF-&#x003ba;B-mediated IFN production</title><p id="Par6">Activation of the nuclear factor-&#x003ba;B (NF-&#x003ba;B) signal pathway is considered as a critical factor for stimulating type I IFN responses against pathogen infection<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Recent research demonstrated that induction of NF-&#x003ba;B- mediated antiviral IFN-&#x003b1; responses could efficiently suppress DENV-2 replication<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. To characterize how THHY inhibits DENV-2 replication, we first analyzed whether THHY treatment could induce NF-&#x003ba;B activity in the presence of DENV. Huh-7 cells were infected by DENV-2 and then incubated with THHY. The total cell lysates were harvested at 0.5, 1, 3, and 6&#x02009;h after treatment, and the phosphorylation status of NF-&#x003ba;B and its upstream regulators including I&#x003ba;B&#x003b1; and IKK&#x003b1;/&#x003b2; were examined by western blotting. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2A</xref>, THHY treatment resulted in the accumulation of phospho-IKK&#x003b1;/&#x003b2; and phospho-NF-&#x003ba;B levels in a time-dependent manner. In addition, we performed NF-&#x003ba;B promoter-based reporter assay to identify whether NF-&#x003ba;B transcriptional activity was induced by THHY. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref>, THHY dose-dependently induced NF-&#x003ba;B promoter activity upon DENV infection (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref>). To further confirm the role of NF-&#x003ba;B on anti-DENV activity of THHY, NF-&#x003ba;B specific inhibitor, CAPE, was employed to inhibit NF-&#x003ba;B activity in the presence of DENV infection. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2C</xref>, THHY effectively reduced DENV protein replication (lanes 1 and 2), and the CAPE treatment attenuated the anti-DENV effect of THHY (lanes 2 and 3). We next examined whether THHY treatment could up-regulate IFN-&#x003b1; levels upon DENV infection. DENV-2-infected Huh-7 cells were incubated with THHY at indicated concentration. The cellular RNA was collected to analyze mRNA levels of FN-&#x003b1;-2 and IFN-&#x003b1;-17 at day 3 post-infection. The results showed that THHY induced both IFN-&#x003b1; RNA level in DENV-2-infected cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3A,B</xref>). Furthermore, we simultaneously measured the secretory protein level of IFN-&#x003b1; in the supernatant by ELISA. As expected, IFN-&#x003b1; secretion was increased by THHY treatment (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3C</xref>). Collectively, these results revealed that THHY inhibits DENV replication via up-regulation of NF-&#x003ba;B-mediated antiviral IFN-&#x003b1; expression.<fig id="Fig2"><label>Figure 2</label><caption><p>THHY inhibits DENV replication via up-regulation of NF-&#x003ba;B activity. (<bold>A</bold>) THHY induces NF-&#x003ba;B activity upon DENV replication. Huh-7 cells were infected by DENV at an MOI of 0.2 and then treated with 20&#x02009;&#x003bc;M THHY. Total cellular protein was harvest at 0,0.5,1,3, and 6&#x02009;h post treatment. NF-&#x003ba;B (P-NF&#x003ba;B), IKK-&#x003b1;/&#x003b2; (P-IKK&#x003b1;/&#x003b2;), and I&#x003ba;B&#x003b1; (P-I&#x003ba;B&#x003b1;) phosphorylation were determined by western blotting with anti-phosphorylated NF-&#x003ba;B, IKK-&#x003b1;/&#x003b2; and I&#x003ba;B&#x003b1; antibodies, respectively. The total NF-&#x003ba;B (NF&#x003ba;B), IKK-&#x003b1;/&#x003b2; (IKK&#x003b1; and IKK&#x003b2;) and I&#x003ba;B&#x003b1; (I&#x003ba;B&#x003b1;) levels were determined by western blotting with anti-NF-&#x003ba;B, IKK-&#x003b1;/&#x003b2;, and I&#x003ba;B&#x003b1; antibodies, respectively. (<bold>B</bold>) THHY induces NF-&#x003ba;B promoter activity upon DENV replication. Huh-7 cells were transiently expressed pNF-&#x003ba;B-Luc and then infected by DENV at an MOI of 0.2. After virus infection, cells were treated with THHY with indicated concentrations, and the luciferase activity was measured at day 3 post-treatment. (<bold>C</bold>) NF-&#x003ba;B specific inhibitor, CAPE, attenuates the anti-DENV effect of THHY. The DENV-infected Huh-7 cells were co-treated with 20&#x02009;&#x003bc;M of THHY and 1&#x02009;&#x003bc;M of CAPE for 3 days. Total cell lysates were harvested for analysis of DENV protein levels by western blotting. The treatment of 0.1% DMSO, marked &#x0201c;0&#x0201d;, was served as a negative control. Error bars represent the means&#x02009;&#x000b1;&#x02009;SD from 3 independent experiments (n&#x02009;=&#x02009;3). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="41598_2018_36714_Fig2_HTML" id="d29e666"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p>THHY inhibits DENV replication via induction of antiviral IFN production. (<bold>A</bold>&#x02013;<bold>C</bold>) DENV-infected Huh-7 cells were incubated with THHY at indicated concentrations. Total cellular RNA was collected for analysis of (<bold>A</bold>) IFN-&#x003b1;-2 and (<bold>B</bold>) IFN-&#x003b1;-17 mRNA levels by qRT-PCR at day 3 post-infection. The supernatant was harvested for measurement of (<bold>C</bold>) IFN-&#x003b1; protein level using ELISA kit. The untreated cells served as control and their expression level was set to 1. The non-THHY treated sample was added 0.1% of DMSO as a negative control. Error bars represent the means&#x02009;&#x000b1;&#x02009;SD from 3 independent experiments (n&#x02009;=&#x02009;3).</p></caption><graphic xlink:href="41598_2018_36714_Fig3_HTML" id="d29e690"/></fig></p></sec><sec id="Sec5"><title>THHY induces antiviral IFN responses through the STAT pathway</title><p id="Par7">Induction of IFN-&#x003b1; should result in the phosphorylation/homodimerization of STAT1/STAT2 which translocates into nucleus to bind the type I IFN-responsive element (ISRE), ultimately stimulates critical antiviral genes expression including OAS1&#x02013;3 and PKR<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. To investigate whether THHY can induce STAT1 and STAT2 phosphorylation in the presence of DENV, the DENV-2-infected Huh-7 cells were incubated with THHY at indicated concentration. After 3 days, total cellular protein was harvested to examine the level of phospho-STAT1 and phospho-STAT2. The results of western blotting showed that THHY treatment increased STAT1 and STAT2 phosphorylation levels in the presence DENV-2 replication (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4A</xref>). Using an ISER-driven luciferase reporter assay, we observed, as expected, that THHY increased ISRE transcriptional activity in a dose-dependent manner (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4B</xref>). Moreover, the results of RT-qPCR revealed that the levels of IFN-stimulated antiviral gene expression were increase by THHY treatment in DENV-2-infected cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4C&#x02013;F</xref>). Collectively, these results support that THHY inhibits DENV-2 replication via upregulation of IFN-&#x003b1; and STAT1/2-triggered antiviral responses.<fig id="Fig4"><label>Figure 4</label><caption><p>THHY inhibits DENV replication by increasing STAT activity and downstream antiviral gene expression. (<bold>A</bold>) THHY enhances STAT1 and 2 phosphorylation. DENV-infected Huh-7 cells were incubated with THHY at indicated concentrations. Total cellular protein was harvested at day 3 post-infection, and STAT1 and STAT2 phosphorylation levels were determined by western blotting with anti-phosphorylated STAT1 (P-STAT1) and STAT2 (P-STAT2) antibodies, respectively. The total STAT1 (STAT1) and STAT2 level (STAT2) were identified by anti- STAT1 and STAT2 antibodies, respectively. (<bold>B</bold>) THHY enhances ISRE activity. Huh-7 cells were transfected with pISRE-Luc and infected with DENV, then followed by incubation of THHY at indicated concentrations. After 3 days treatment, luciferase activity was analyzed. (<bold>C</bold>&#x02013;<bold>F</bold>) THHY induces antiviral gene expression. Huh-7 cells were incubated with THHY at indicated concentrations. The treatment of 0.1% DMSO, marked &#x0201c;0&#x0201d;, was served as a negative control. The cellular RNA was harvested to analyze the relative mRNA level of (<bold>C</bold>) OAS1, (<bold>D</bold>) OAS2, (<bold>E</bold>) OAS3 and (<bold>F</bold>) PKR by qRT-PCR. Error bars represent the means&#x02009;&#x000b1;&#x02009;SD from 3 independent experiments (n&#x02009;=&#x02009;3). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="41598_2018_36714_Fig4_HTML" id="d29e745"/></fig></p></sec><sec id="Sec6"><title>THHY protects ICR suckling mice against life-threatening DENV infection</title><p id="Par8">We further used the ICR suckling mice to evaluate the anti-DENV activity of THHY <italic>in vivo</italic><sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Six days old ICR suckling mice were inoculated with active or heat-inactivated DENV-2 (iDENV) by intracerebral injection (i.c. injection), and mice received iDENV served as a negative control. The DENV-2-infected mice were received 5&#x02009;mg/kg of THHY or saline by intracerebral injection. The clinical scores, body weight and survival rate were recorded every day. After 6 days infection, mice were sacrificed, and the brain tissues were harvested to analyze viral titer using plaque assay. The results showed that the DENV-2-infected mice receiving THHY decreased approximately 40% clinical scores compared to mice receiving saline (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5A</xref>). In addition, THHY treatment recovered about 95% the body weight of infected mice, as compared to iDENV-infected mice receiving saline (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5B</xref>). Notably, THHY increased 60% the survival rate compared with saline treatment in DENV-2-infected mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5C</xref>). We further evaluated the decrease in viral titer in DENV-infected brain tissue with THHY treatment (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5D</xref>).<fig id="Fig5"><label>Figure 5</label><caption><p>THHY protects ICR suckling mice against lethal DENV infection. (<bold>A</bold>&#x02013;<bold>D</bold>) Six-day-old ICR suckling mice were i.c. injected with heat-inactivated DENV (iDENV, filled circles, n&#x02009;=&#x02009;5) or active DENV. DENV-infected mice received saline (DENV, filled squares, n&#x02009;=&#x02009;5) or 5&#x02009;mg/kg (DENV&#x02009;+&#x02009;THHY 5&#x02009;mg/kg, filled triangles, n&#x02009;=&#x02009;5) THHY inoculation at 1,3,5 days post infection. The (<bold>A</bold>) clinical scores, (<bold>B</bold>) body weight, and (<bold>C</bold>) survival rates were monitored daily until sacrifice at day 6 post-infection. Disease severity was scored as follows: 0: no symptoms, 1: slight weight loss and ruffled hair, 2: slowing of activity, 3: asthenia, 4: paralysis and mortal ill, and 5: death. (<bold>D</bold>) The brain tissue was collected for determination of viral titer by plaque-forming assay. Error bars represent the means&#x02009;&#x000b1;&#x02009;SD. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><graphic xlink:href="41598_2018_36714_Fig5_HTML" id="d29e800"/></fig></p><p id="Par9">Currently, two direct antiviral agents, NITD-008 and balapiravir, have entered clinical trial phase. However, both trials have been stopped due to toxicity and lack of potency<sup><xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref></sup>. In the present study, we found that THHY, extracted from avocado, exhibits anti-DENV activity <italic>in vitro</italic> and <italic>in vivo</italic> (Figs&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig5" ref-type="fig">5</xref>). Avocado is known to be a healthy fruit which contains many phytochemicals with high antioxidant activity<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. An association between increased oxidative stress and disease severity of DENV-induced pathogenesis has been reported<sup><xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref></sup>. In addition to blockage of DENV replication, the avocado extracts will facilitate research into the nutritional food additives used in reducing the risk of DENV-induced DHS/DSS in DENV-infected patients. In the study of inhibitory properties against DENV of THHY, we clearly verified that THHY suppressed DENV replication through up-regulation of NF-&#x003ba;B-mediated antiviral IFN responses (Figs&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>&#x02013;<xref rid="Fig4" ref-type="fig">4</xref>), which is consistent with previous reports that stimulation of IFN-induced antiviral pathway is a promising strategy against DENV infection<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. In the antiviral IFN signaling pathway, the RIG-I-mediated MAVS is a major signaling pathway activating the NF-&#x003ba;B pathway and its downstream antiviral IFN responses<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. In addition, activation of RIG-I triggers IRF3 and IRF7 expression to induce the antiviral IFN pathway<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. To gain a thorough understanding of the antiviral action of THHY, further investigation of the correlation between THHY and RIG-I/MAVS-mediated antiviral IFN responses is warranted. Moreover, several reports have demonstrated that DENV interrupts and escapes innate host immune responses by interfering IFN mediators. For instance, DENV protease has been indicated to target MAVS<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, DENV NS4B has been demonstrated to block STAT1 phosphorylation<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, and DENV NS5 has been reported to block the JAK-STAT2 pathway by degradation of STAT2 protein<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Further experiments will be performed to clarify how THHY interrupts the DENV protein-inhibited IFN pathway. In conclusion, our study identified THHY, one of the active constituents of avocado fruit, as a potential agent against DENV infection <italic>in vitro</italic> and <italic>in vivo</italic>. Our results further revealed the detailed mechanism by which THHY suppresses DENV replication via up-regulation of NF-&#x003ba;B&#x02013;mediated antiviral IFN responses and downstream antiviral gene expression. Additionally, THHY protected ICR suckling mice against death by DENV infection <italic>in vivo</italic>, allowing avocado fruit to serve as a potential dietary resource to develop a supplement for the treatment DENV infection and DENV-related diseases.</p></sec></sec><sec id="Sec7" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec8"><title>Ethics statement and experimental animals</title><p id="Par10">In this study, the six-day-old ICR suckling mice purchased from BioLasco Taiwan Co Ltd were maintained under specific pathogen-free conditions for the anti-DENV efficacy of THHY. The experimental protocol was approved by the Animal Research Committee of Kaohsiung Medical University of Taiwan (IACUC, 103164) according to the guidance of the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals.</p></sec><sec id="Sec9"><title>Chemicals</title><p id="Par11">(2<italic>R</italic>,4<italic>R</italic>)-1,2,4-trihydroxyheptadec-16-yne (THHY) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B</xref>) was extracted from the unripe pulp of avocado<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Ribavirin was purchased from Sigma Chemical Co. (St. Louis, MO, USA). The compound was dissolved in a 100&#x02009;mM stock solution of dimethyl sulfoxide (DMSO) and stored at &#x02212;20&#x000b0;&#x02009;C. In each reaction, the final DMSO concentration was 0.1%.</p></sec><sec id="Sec10"><title>Cells and virus</title><p id="Par12">Human hepatoma Huh-7 cells were cultured in Dulbecco&#x02019;s Modified Eagle&#x02019;s medium (DMEM) supplemented with 10% fetal bovine serum, 1% nonessential amino acids, and 1% antibiotic&#x02013;antimycotic at 37&#x02009;&#x000b0;C. C6/36 mosquito cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 1% nonessential amino acids, 1% L-glutamine, 1% sodium pyruvate, and 1% antibiotic&#x02013;antimycotic in a 5% CO2 atmosphere at 37&#x02009;&#x000b0;C. DENV-2 strain 16681 was kindly provided by Dr. Huey-Nan Wu (Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan). The other types of DENV (DENV-1:DN8700828; DENV-3: DN8700829; DENV-4: S9201818) were provided by the Centers for Disease Control, Department of Health, Taiwan. DENV was propagated in mosquito C6/36 cells (Hsu <italic>et al</italic>., 2012; Lee <italic>et al</italic>., 2015). Virus titer was determined by the TCID<sub>50</sub> method<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p></sec><sec id="Sec11"><title>Plasmid</title><p id="Par13">pISRE-Luc harboring IFN-stimulated response element (ISRE)-driven firefly luciferase was used to measure IFN-stimulated transcriptional activity (Stratagene, Agilent Technologies, Palo Alto, CA, USA). pNF-&#x003ba;B-Luc harboring NF-&#x003ba;B binding element-driven firefly luciferase was used to measure NF-&#x003ba;B transcriptional activity (BD Biosciences Clontech, Palo Alto, CA, USA)<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p></sec><sec id="Sec12"><title>Quantification of RNA levels</title><p id="Par14">Total cellular RNA was extracted by using an RNA Purification Kit (GMbiolab Co, Ltd., Taichung, Taiwan) following the manufacturer&#x02019;s instructions. The relative DENV RNA or cellular mRNA levels were measured by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) with specific primers (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) following normalization of cellular glyceraldehyde-3-phosphate dehydrogenase (<italic>gapdh</italic>) mRNA level<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>oligonucleotide sequences for real-time RT-PCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Oligonucleotide Name</th><th>Sequence 5&#x02032;-3&#x02032;</th></tr><tr><th colspan="2">DENV gene oligonucleotide sequences</th></tr></thead><tbody><tr><td>Type 1&#x02013;5&#x02032; NS5</td><td>5&#x02032;- CAGGTCAAACGCAGCTATTG</td></tr><tr><td>Type 1&#x02013;3&#x02032; NS5</td><td>5&#x02032;- CCACTCCACTGAGTGAATTC</td></tr><tr><td>Type 2&#x02013;5&#x02032; NS5</td><td>5&#x02032;- TGTATGCCGATGACACCGCA</td></tr><tr><td>Type 2&#x02013;3&#x02032; NS5</td><td>5&#x02032;- TCTTTGCACACGGACCACCT</td></tr><tr><td>Type 3&#x02013;5&#x02032; NS5</td><td>5&#x02032;- TCAGAACTAACGCAGCCATG</td></tr><tr><td>Type 3&#x02013;5&#x02032; NS5</td><td>5&#x02032;- AGAGTTTTCACGCGAGAACC</td></tr><tr><td>Type 4&#x02013;5&#x02032; NS5</td><td>5&#x02032;- AGATCAAACGCAGCCATAGG</td></tr><tr><td>Type 4&#x02013;5&#x02032; NS5</td><td>5&#x02032;- CTTCCACTCCACTCCATGAA</td></tr><tr><td colspan="2">
<bold>Human gene oligonucleotide sequences</bold>
</td></tr><tr><td>5&#x02032; GAPDH</td><td>5&#x02032;-GTCTTCACCACCATGGAGAA</td></tr><tr><td>3&#x02032; GAPDH</td><td>5&#x02032;-ATGGCATGGACTGTGGTCAT</td></tr><tr><td>5&#x02032; OAS1</td><td>5&#x02032;- CAAGCTTAAGAGCCTCATCC</td></tr><tr><td>3&#x02032; OAS1</td><td>5&#x02032;- TGGGCTGTGTTGAAATGTGT</td></tr><tr><td>5&#x02032; OAS2</td><td>5&#x02032;- ACAGCTGAAAGCCTTTTGGA</td></tr><tr><td>3&#x02032; OAS2</td><td>5&#x02032;- GCATTAAAGGCAGGA AGCAC</td></tr><tr><td>5&#x02032; OAS3</td><td>5&#x02032;- CACTGACATCCCAGACGATG</td></tr><tr><td>3&#x02032; OAS3</td><td>5&#x02032;- GATCAGGCTCTTCAGCTTGG</td></tr><tr><td>5&#x02032; PKR</td><td>5&#x02032;- ATGATGGAAAGCGAACAAGG</td></tr><tr><td>3&#x02032; PKR</td><td>5&#x02032;- GAGATGATGCCATCCCGTAG</td></tr><tr><td>5&#x02032; IFN-alpha 2</td><td>5&#x02032;-GCA AGT CAA GCT GCT CTG TG</td></tr><tr><td>3&#x02032; IFN-alpha 2</td><td>5&#x02032;-GAT GGT TTC AGC CTT TTG GA</td></tr><tr><td>5&#x02032; IFN-alpha 17</td><td>5&#x02032;-AGG AGT TTG ATG GCA ACC AG</td></tr><tr><td>3&#x02032; IFN-alpha 17</td><td>5&#x02032;-CAT CAG GGG AGT CTC TTC CA</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Western blotting</title><p id="Par15">The procedure of western blotting was performed as described before<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The listed antibodies were used in this study, including anti-DENV NS2B antibody (GeneTex, Inc, Irvine, CA), NF-&#x003ba;B antibody (Cell Signaling Technology, Inc. Beverly, MA), IKK-&#x003b1; antibody (Cell Signaling), IKK-&#x003b2; antibody (Cell Signaling), I&#x003ba;B&#x003b1; antibody (Cell Signaling), STAT1 antibody (GeneTex), STAT2 antibody (GeneTex), phosphorylated NF-&#x003ba;B antibody (Cell Signaling), phosphorylated IKK-&#x003b1;/&#x003b2; antibody (Cell Signaling), phosphorylated I&#x003ba;B&#x003b1; antibody (Cell Signaling), phosphorylated STAT1 (Tyr701) antibody (Cell Signaling), phosphorylated STAT2 (Tyr690) antibody (Cell Signaling), and anti-GAPDH antibody (GeneTex). The GAPDH protein level served as an internal control<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. The DENV nonstructural protein NS2B served as an indicator to represent viral protein synthesis.</p></sec><sec id="Sec14"><title>Transfection</title><p id="Par16">Huh-7 cells were seeded in 24-well plates for 24&#x02009;h, and the cells were transfected with the indicated plasmids by TransIT-X2&#x000ae; transfection reagent (Mirus Bio LLC, Madison, WI, USA) according to the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec15"><title>Measurement of luciferase activity</title><p id="Par17">Luciferase expression was determined by using the Steady-Glo Luciferase Assay System (Promega Corporation, Madison, WI, USA) in accordance with the manufacturer&#x02019;s instructions.</p></sec><sec id="Sec16"><title>Analysis of extracellular IFN-&#x003b1; protein level</title><p id="Par18">Huh-7 cells were infected with DENV at an MOI of 0.2 for 2&#x02009;h, followed by THHY treatment for 3 days. The supernatant was collected to measure IFN-&#x003b1; concentration by using a human IFN-&#x003b1; ELISA kit (Life Science) in accordance with the manufacturer&#x02019;s protocol. Absorbance of each condition was detected at 450&#x02009;nm using an Epoch microplate spectrophotometer (BioTek Instruments Inc, Winooski, VT, USA).</p></sec><sec id="Sec17"><title>Anti-DENV activity <italic>in vivo</italic></title><p id="Par19">The anti-DENV activity <italic>in vivo</italic> was determined as described before<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. In brief, Six-day-old ICR suckling mice were randomly divided into three groups (n&#x02009;=&#x02009;5): Group 1 received heat-inactivated DENV and saline treatment (iDENV); Group 2 received DENV and saline treatment (DENV); and Group 3 received DENV and 5&#x02009;mg/kg of THHY treatment at 1, 3, and 5 days post infection (DENV&#x02009;+&#x02009;THHY 5&#x02009;mg/kg). The suckling mice were sacrificed at day 6 post-infection by carbon dioxide euthanasia. For determination of virus titer, brain tissues were collected, weighed and homogenized in RPMI 1640 medium. Subsequently, the supernatants were collected and stored at &#x02212;80&#x02009;&#x000b0;C after centrifugation at 8000&#x02009;rpm for 15&#x02009;min at 4&#x02009;&#x000b0;C.</p></sec><sec id="Sec18"><title>Measurement of viral titers</title><p id="Par20">The determination of viral titer was performed as described before<xref ref-type="bibr" rid="CR20">20</xref>. In brief, Huh-7 cells were infected by serially diluted virus. Following incubation for 2&#x02009;h, the virus inoculum was removed and replaced with complete growth medium. After 3 days, the DENV-infected cells were fixed with 4% paraformaldehyde for 20&#x02009;minutes on ice and followed by permeabilization with 0.2% Triton X-100 for 20&#x02009;minutes on ice. The fixed cells were blocked in 4% BSA for 2&#x02009;hours, followed by incubation of anti-prM antibody (1:1000, GeneTex) over night. The cells were washed with PBS for 6 times followed by incubation with Alexa Flour 488-conjugated goat anti-rabbit antibody (1:1000, Life Technologies Corporation, Carlsbad, California, USA) for 1&#x02009;hour. The cells were washed with PBS for 6 times and counterstained with DAPI (1:1000, Life Technologies Corporation, Carlsbad, California, USA) for 5&#x02009;minutes. The cells were washed with PBS for 6 times and observed with EVOS FL Cell Imaging System (Life Technologies Corporation, Carlsbad, California, USA), and the virus titer was calculated by the TCID<sub>50</sub> method.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p id="Par21">Data are represented as mean&#x02009;&#x000b1;&#x02009;standard deviations from at least three independent experiments (n&#x02009;&#x02265;&#x02009;3). Statistical significance was calculated using Student&#x02019;s <italic>t</italic> test for differences between 2 data groups (drug-treated and -untreated cells). The experimental values of n indicate the number of experiments used. Results were considered significant at *P&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec20"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2018_36714_MOESM1_ESM.pdf"><caption><p>Supplementary information</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Electronic supplementary material</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1038/s41598-018-36714-4.</p></sec><ack><title>Acknowledgements</title><p>The authors would like to thank Dr. Charles Rice (Rockefeller University and Aapth, LCC, USA) for kindly supporting human hepatoma cell; Huh-7 and Dr. Huey-Nan Wu (Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan) for kindly supporting DENV type 2 strain PL046. The authors also thank to Centers for Disease Control, Department of Health, Taiwan, for kindly supporting 4 serotypes of dengue virus. This work was supported by Ministry of Science and Technology of Taiwan under Grant (MOST104&#x02013;2320-B-037&#x02013;025-MY3 and MOST107&#x02013;2311-B-037&#x02013;005-MY3), Chi-Mei Medical Center and Kaohsiung Medical University Research Foundation (107CM-KMU-03) and Kaohsiung Medical University (grant No. KMU-DK107011 and KMU-DK108010).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Jin-Ching Lee, Yu-Hsuan Wu and Hsun-Shuo Chang performed the experimental design. Chin-Kai Tseng, Ho-Cheng Wu, Chih-Ku Wei, and Chun-Kuang Lin performed the research as described in the Material and Method. Ih-Sheng Chen contributed essential reagents. Yu-Hsuan Wu, Chin-Kai Tseng and Ho-Cheng Wu analyzed the data. Jin-Ching Lee and Hsun-Shuo Chang wrote the paper.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p>The authors declare no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>OJ</given-names></name><etal/></person-group><article-title>Refining the global spatial limits of dengue virus transmission by evidence-based consensus</article-title><source>PLoS neglected tropical diseases</source><year>2012</year><volume>6</volume><fpage>e1760</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0001760</pub-id><?supplied-pmid 22880140?><pub-id pub-id-type="pmid">22880140</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Characterization of the activity of 2&#x02032;-C-methylcytidine against dengue virus replication</article-title><source>Antiviral research</source><year>2015</year><volume>116</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.01.002</pub-id><?supplied-pmid 25614455?><pub-id pub-id-type="pmid">25614455</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Structure of dengue virus: implications for flavivirus organization, maturation, and fusion</article-title><source>Cell</source><year>2002</year><volume>108</volume><fpage>717</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00660-8</pub-id><pub-id pub-id-type="pmid">11893341</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>JK</given-names></name><etal/></person-group><article-title>First experimental <italic>in vivo</italic> model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies</article-title><source>PLoS pathogens</source><year>2014</year><volume>10</volume><fpage>e1004031</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004031</pub-id><?supplied-pmid 24699622?><pub-id pub-id-type="pmid">24699622</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalrymple</surname><given-names>NA</given-names></name><name><surname>Cimica</surname><given-names>V</given-names></name><name><surname>Mackow</surname><given-names>ER</given-names></name></person-group><article-title>Dengue Virus NS Proteins Inhibit RIG-I/MAVS Signaling by Blocking TBK1/IRF3 Phosphorylation: Dengue Virus Serotype 1 NS4A Is a Unique Interferon-Regulating Virulence Determinant</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e00553</fpage><lpage>00515</lpage><pub-id pub-id-type="doi">10.1128/mBio.00553-15</pub-id><?supplied-pmid 25968648?><pub-id pub-id-type="pmid">25968648</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chareonsirisuthigul</surname><given-names>T</given-names></name><name><surname>Kalayanarooj</surname><given-names>S</given-names></name><name><surname>Ubol</surname><given-names>S</given-names></name></person-group><article-title>Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells</article-title><source>The Journal of general virology</source><year>2007</year><volume>88</volume><fpage>365</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1099/vir.0.82537-0</pub-id><?supplied-pmid 17251552?><pub-id pub-id-type="pmid">17251552</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martina</surname><given-names>BE</given-names></name><name><surname>Koraka</surname><given-names>P</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>Dengue virus pathogenesis: an integrated view</article-title><source>Clinical microbiology reviews</source><year>2009</year><volume>22</volume><fpage>564</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1128/CMR.00035-09</pub-id><?supplied-pmid 19822889?><pub-id pub-id-type="pmid">19822889</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>MG</given-names></name><name><surname>Kouri</surname><given-names>G</given-names></name></person-group><article-title>Dengue diagnosis, advances and challenges</article-title><source>International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases</source><year>2004</year><volume>8</volume><fpage>69</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2003.03.003</pub-id><pub-id pub-id-type="pmid">14732325</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>WJ</given-names></name><name><surname>Bielefeldt-Ohmann</surname><given-names>H</given-names></name></person-group><article-title>Dengue viral infections; pathogenesis and epidemiology</article-title><source>Microbes and infection</source><year>2000</year><volume>2</volume><fpage>1041</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(00)01258-2</pub-id><pub-id pub-id-type="pmid">10967284</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression</article-title><source>Journal of virology</source><year>2005</year><volume>79</volume><fpage>5414</fpage><lpage>5420</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.9.5414-5420.2005</pub-id><?supplied-pmid 15827155?><pub-id pub-id-type="pmid">15827155</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiscott</surname><given-names>J</given-names></name></person-group><article-title>Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response</article-title><source>Cytokine &#x00026; growth factor reviews</source><year>2007</year><volume>18</volume><fpage>483</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2007.06.002</pub-id><pub-id pub-id-type="pmid">17706453</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>SE</given-names></name><name><surname>Mossman</surname><given-names>KL</given-names></name></person-group><article-title>Danger, diversity and priming in innate antiviral immunity</article-title><source>Cytokine &#x00026; growth factor reviews</source><year>2014</year><volume>25</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.07.002</pub-id><pub-id pub-id-type="pmid">25081316</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>MicroRNA-30e* suppresses dengue virus replication by promoting NF-kappaB-dependent IFN production</article-title><source>PLoS neglected tropical diseases</source><year>2014</year><volume>8</volume><fpage>e3088</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0003088</pub-id><?supplied-pmid 25122182?><pub-id pub-id-type="pmid">25122182</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Grandvaux</surname><given-names>N</given-names></name></person-group><article-title>STAT2 and IRF9: Beyond ISGF3</article-title><source>Jak-Stat</source><year>2013</year><volume>2</volume><fpage>e27521</fpage><pub-id pub-id-type="doi">10.4161/jkst.27521</pub-id><?supplied-pmid 24498542?><pub-id pub-id-type="pmid">24498542</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling</article-title><source>PLoS pathogens</source><year>2013</year><volume>9</volume><fpage>e1003265</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003265</pub-id><?supplied-pmid 23555265?><pub-id pub-id-type="pmid">23555265</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections</article-title><source>Journal of virology</source><year>2010</year><volume>84</volume><fpage>8332</fpage><lpage>8341</lpage><pub-id pub-id-type="doi">10.1128/JVI.02199-09</pub-id><?supplied-pmid 20534863?><pub-id pub-id-type="pmid">20534863</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon-Loriere</surname><given-names>E</given-names></name><etal/></person-group><article-title>High Anti-Dengue Virus Activity of the OAS Gene Family Is Associated With Increased Severity of Dengue</article-title><source>The Journal of infectious diseases</source><year>2015</year><volume>212</volume><fpage>2011</fpage><lpage>2020</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv321</pub-id><?supplied-pmid 26063222?><pub-id pub-id-type="pmid">26063222</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Dengue virus targets the adaptor protein MITA to subvert host innate immunity</article-title><source>PLoS pathogens</source><year>2012</year><volume>8</volume><fpage>e1002780</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002780</pub-id><?supplied-pmid 22761576?><pub-id pub-id-type="pmid">22761576</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Jordan</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses</article-title><source>Journal of virology</source><year>2005</year><volume>79</volume><fpage>8004</fpage><lpage>8013</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.13.8004-8013.2005</pub-id><?supplied-pmid 15956546?><pub-id pub-id-type="pmid">15956546</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway</article-title><source>Scientific reports</source><year>2017</year><volume>7</volume><fpage>45171</fpage><pub-id pub-id-type="doi">10.1038/srep45171</pub-id><?supplied-pmid 28338050?><pub-id pub-id-type="pmid">28338050</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diwaker</surname><given-names>D</given-names></name><name><surname>Mishra</surname><given-names>KP</given-names></name><name><surname>Ganju</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>SB</given-names></name></person-group><article-title>Rhodiola inhibits dengue virus multiplication by inducing innate immune response genes RIG-I, MDA5 and ISG in human monocytes</article-title><source>Archives of virology</source><year>2014</year><volume>159</volume><fpage>1975</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1007/s00705-014-2028-0</pub-id><?supplied-pmid 24590566?><pub-id pub-id-type="pmid">24590566</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinpelu</surname><given-names>DA</given-names></name><name><surname>Aiyegoro</surname><given-names>OA</given-names></name><name><surname>Akinpelu</surname><given-names>OF</given-names></name><name><surname>Okoh</surname><given-names>AI</given-names></name></person-group><article-title>Stem bark extract and fraction of Persea americana (Mill.) exhibits bactericidal activities against strains of bacillus cereus associated with food poisoning</article-title><source>Molecules</source><year>2014</year><volume>20</volume><fpage>416</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.3390/molecules20010416</pub-id><?supplied-pmid 25558854?><pub-id pub-id-type="pmid">25558854</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brai</surname><given-names>BI</given-names></name><name><surname>Adisa</surname><given-names>RA</given-names></name><name><surname>Odetola</surname><given-names>AA</given-names></name></person-group><article-title>Hepatoprotective properties of aqueous leaf extract of Persea Americana, Mill (Lauraceae) &#x02018;avocado&#x02019; against CCL4-induced damage in rats</article-title><source>African journal of traditional, complementary, and alternative medicines: AJTCAM</source><year>2014</year><volume>11</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.4314/ajtcam.v11i2.2</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveh</surname><given-names>E</given-names></name><name><surname>Werman</surname><given-names>MJ</given-names></name><name><surname>Sabo</surname><given-names>E</given-names></name><name><surname>Neeman</surname><given-names>I</given-names></name></person-group><article-title>Defatted avocado pulp reduces body weight and total hepatic fat but increases plasma cholesterol in male rats fed diets with cholesterol</article-title><source>The Journal of nutrition</source><year>2002</year><volume>132</volume><fpage>2015</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1093/jn/132.7.2015</pub-id><pub-id pub-id-type="pmid">12097685</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neeman</surname><given-names>I</given-names></name><name><surname>Lifshitz</surname><given-names>A</given-names></name><name><surname>Kashman</surname><given-names>Y</given-names></name></person-group><article-title>New antibacterial agent isolated from the avocado pear</article-title><source>Applied microbiology</source><year>1970</year><volume>19</volume><fpage>470</fpage><lpage>473</lpage><?supplied-pmid 4985830?><pub-id pub-id-type="pmid">4985830</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>MM</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> activity of extracts of Persea americana leaves on acyclovir-resistant and phosphonoacetic resistant Herpes simplex virus</article-title><source>Phytomedicine: international journal of phytotherapy and phytopharmacology</source><year>1997</year><volume>4</volume><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/S0944-7113(97)80045-1</pub-id><pub-id pub-id-type="pmid">23195586</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>HS</given-names></name><name><surname>Peng</surname><given-names>CF</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>IS</given-names></name></person-group><article-title>Secondary metabolites from the unripe pulp of Persea americana and their antimycobacterial activities</article-title><source>Food chemistry</source><year>2012</year><volume>135</volume><fpage>2904</fpage><lpage>2909</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.07.073</pub-id><?supplied-pmid 22980888?><pub-id pub-id-type="pmid">22980888</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>NM</given-names></name><etal/></person-group><article-title>A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients</article-title><source>The Journal of infectious diseases</source><year>2013</year><volume>207</volume><fpage>1442</fpage><lpage>1450</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis470</pub-id><?supplied-pmid 22807519?><pub-id pub-id-type="pmid">22807519</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>An adenosine nucleoside inhibitor of dengue virus</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2009</year><volume>106</volume><fpage>20435</fpage><lpage>20439</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907010106</pub-id><?supplied-pmid 19918064?><pub-id pub-id-type="pmid">19918064</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anusuya</surname><given-names>S</given-names></name><name><surname>Velmurugan</surname><given-names>D</given-names></name><name><surname>Gromiha</surname><given-names>MM</given-names></name></person-group><article-title>Identification of dengue viral RNA-dependent RNA polymerase inhibitor using computational fragment-based approaches and molecular dynamics study</article-title><source>Journal of biomolecular structure &#x00026; dynamics</source><year>2016</year><volume>34</volume><fpage>1512</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1080/07391102.2015.1081620</pub-id><pub-id pub-id-type="pmid">26262439</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibitory effect of glutathione on oxidative liver injury induced by dengue virus serotype 2 infections in mice</article-title><source>PloS one</source><year>2013</year><volume>8</volume><fpage>e55407</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055407</pub-id><?supplied-pmid 23383181?><pub-id pub-id-type="pmid">23383181</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soundravally</surname><given-names>R</given-names></name><etal/></person-group><article-title>Oxidative stress induced changes in plasma protein can be a predictor of imminent severe dengue infection</article-title><source>Acta tropica</source><year>2008</year><volume>106</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2008.03.001</pub-id><?supplied-pmid 18420173?><pub-id pub-id-type="pmid">18420173</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seet</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Oxidative damage in dengue fever</article-title><source>Free radical biology &#x00026; medicine</source><year>2009</year><volume>47</volume><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.04.035</pub-id><pub-id pub-id-type="pmid">19427377</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>LM</given-names></name></person-group><article-title>The role of nuclear factor kappaB in the interferon response</article-title><source>Journal of interferon &#x00026; cytokine research: the official journal of the International Society for Interferon and Cytokine Research</source><year>2011</year><volume>31</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1089/jir.2011.0028</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents</article-title><source>Scientific reports</source><year>2017</year><volume>7</volume><fpage>44701</fpage><pub-id pub-id-type="doi">10.1038/srep44701</pub-id><?supplied-pmid 28317866?><pub-id pub-id-type="pmid">28317866</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-kappaB- and MAPK-ERK1/2-mediated COX-2 expression</article-title><source>British journal of pharmacology</source><year>2015</year><pub-id pub-id-type="doi">10.1111/bph.13233</pub-id><?supplied-pmid 26359950?><pub-id pub-id-type="pmid">26359950</pub-id></element-citation></ref></ref-list></back></article>